KRT18 (Keratin 18)

Our integrative analysis provides a comprehensive molecular and cellular atlas of BE. These findings enhance current understanding of BE pathogenesis and offer clinically relevant candidates for early detection and targeted intervention.

Integrating single-cell and bulk transcriptomes links malignant epithelial state programs to prognosis, yields a practical eight-gene risk model validated in multiple LUAD cohorts, and nominates FAM189A2 as a putative tumor suppressor and potential biomarker in lung cancer. These findings suggest testable strategies for risk stratification and therapy selection that warrant prospective evaluation.

The expression pattern of TAMs also changed from meningioma to brain tissue. Additional studies are needed to confirm these findings and further reveal how we can target meningioma brain invasion.

Their transcriptomic features and derived gene signatures may serve as biomarkers of metastatic potential and indicators of disease progression in prostate cancer. However, their causal role in metastasis and impact on survival remain to be determined.

These findings provide evidence that chemotherapy significantly alters both the ovarian germ cells and stroma, emphasizing the need to further investigate the underlying molecular mechanisms and their impact on ovarian function and fertility preservation. They also suggest target proteins which may drive these chemotherapy-associated ovarian damage for future investigations.

Our study establishes a ferroptosis-related signature for prognostic prediction in pancreatic cancer and identifies NOTCH2 as a critical prognostic biomarker. NOTCH2 may promote pancreatic cancer progression by suppressing ferroptosis, highlighting it as a potential therapeutic target.

It acts as an inhibitor of the oncogenic protein KRT18 in melanoma and prevents the progression of highly metastatic melanoma. Future research should explore the signalling pathways and molecular mechanisms of honokiol action and its synergistic effects at the cellular level and help to develop methods for delivering honokiol to the organism by nanocarriers to improve selective therapies in some diseases.

Therefore, KRT18 may serve as a biomarker for the prognosis and diagnosis of LUAD and also represents a potential target for immunotherapy.

Treating the spheroids with MRTX1133 revealed enhanced drug response profiles compared to 2D cultures. This study underscores the critical importance of 3D multicellular model in preclinical drug screening and their potential to bridge the gap between in vitro studies and clinical outcomes.

Our research provides a paired primary model of treatment-naïve and radioresistant disease to address mechanisms of therapy resistance, while expanding the repertoire of localized prostate cancer cell lines for the research community. In addition, our findings present NNMT as a potential therapeutic target for sensitization of radioresistant disease.

Our findings reveal numerous plasma proteins linked to metabolic-related diseases. These findings offer fresh insights into the etiology, diagnostics, and treatment of these conditions.

RBP signature genes can serve as biomarkers for testicular cancer and play a role in predicting tumor metastasis and therapeutic efficacy.